scholarly journals Solid lipid nanoparticle induced apoptosis of macrophages via a mitochondrial-dependent pathway in vitro and in vivo

2019 ◽  
Vol Volume 14 ◽  
pp. 3283-3295 ◽  
Author(s):  
Wan-Li Liang ◽  
Lan Xiao ◽  
Hong-Wei Gu ◽  
Xiao-Jun Li ◽  
Yu-Sang Li ◽  
...  
Keyword(s):  
Solid Lipid Nanoparticle ◽  
Solid Lipid ◽  
Lipid Nanoparticle ◽  
Induced Apoptosis ◽  
Dependent Pathway

Application of Novel Solid Lipid Nanoparticle (SLN)-Gene Vector Formulations Based on a Dimeric HIV-1 TAT-Peptide in Vitro and in Vivo

2004 ◽  
Vol 21 (9) ◽  
pp. 1662-1669 ◽  
Author(s):  
Carsten Rudolph ◽  
Ulrike Schillinger ◽  
Aurora Ortiz ◽  
Kerstin Tabatt ◽  
Christian Plank ◽  
...  
Keyword(s):  
Gene Vector ◽  
Tat Peptide ◽  
Solid Lipid Nanoparticle ◽  
Solid Lipid ◽  
Lipid Nanoparticle ◽  
Hiv 1

scholarly journals Solid Lipid Nanoparticle Formulations of Docetaxel Prepared with High Melting Point Triglycerides: In Vitro and in Vivo Evaluation

2014 ◽  
Vol 11 (4) ◽  
pp. 1239-1249 ◽  
Author(s):  
Youssef Wahib Naguib ◽  
B. Leticia Rodriguez ◽  
Xinran Li ◽  
Stephen D. Hursting ◽  
Robert O. Williams ◽  
...  
Keyword(s):  
Melting Point ◽  
High Melting ◽  
Solid Lipid Nanoparticle ◽  
High Melting Point ◽  
In Vivo Evaluation ◽  
Solid Lipid ◽  
Lipid Nanoparticle

scholarly journals Preparation and Evaluation of Carbamazepine Solid Lipid Nanoparticle for Alleviating Seizure Activity in Pentylenetetrazole-Kindled Mice

Molecules ◽  
2019 ◽  
Vol 24 (21) ◽  
pp. 3971 ◽  
Author(s):  
Mona Qushawy ◽  
Kousalya Prabahar ◽  
Mohammed Abd-Alhaseeb ◽  
Shady Swidan ◽  
Ali Nasr
Keyword(s):  
Histopathological Examination ◽  
In Vitro Release ◽  
Aqueous Dispersion ◽  
Entrapment Efficiency ◽  
Anticonvulsant Effect ◽  
Solid Lipid Nanoparticle ◽  
Solid Lipid ◽  
Lipid Nanoparticle

Objectives: The study aimed to prepare carbamazepine in solid lipid nanoparticle form (CBZ-SLN) in order to enhance its anticonvulsant effect. Method: Eight formulations of CBZ-SLNs were prepared by homogenization and ultra-sonication techniques. Results: The prepared CBZ-SLN showed a high entrapment efficiency% (39.66 ± 2.42%–71.91 ± 1.21%), a small particle size (45.11 ± 6.72–760.7 ± 5.25 nm), and a negative zeta potential (from −21.5 ± 1.02 to −38.4 ± 1.32 mv). The in vitro release study showed the slow release of CBZ from SLNs compared to CBZ aqueous dispersion (p < 0.05). The infrared spectroscopy and the thermal analysis revealed the compatibility of the drug with other ingredients and the presence of drug in the more soluble amorphous estate, respectively. The in vivo study on mice revealed that the CBZ-SLN had a higher anticonvulsant efficacy than CBZ aqueous dispersion after a lethal and chronic dose of pentylenetetrazole (PTZ) (p < 0.05). The histopathological examination of the hippocampus revealed a decrease in the percentage of degeneration in mice treated with the CBZ-SLN compared to the PTZ and CBZ groups. Conclusion: CBZ can be formulated as SLN with higher anticonvulsant activity than free CBZ aqueous dispersion.

Solid lipid nanoparticle loaded with paromomycin: in vivo efficacy against Leishmania tropica infection in BALB/c mice model

2016 ◽  
Vol 100 (16) ◽  
pp. 7051-7060 ◽  
Author(s):  
Maryam Heidari-Kharaji ◽  
Tahereh Taheri ◽  
Delaram Doroud ◽  
Sima Habibzadeh ◽  
Sima Rafati
Keyword(s):  
Leishmania Tropica ◽  
Solid Lipid Nanoparticle ◽  
Mice Model ◽  
In Vivo Efficacy ◽  
Solid Lipid ◽  
Lipid Nanoparticle

Design and In Vitro Evaluation of Solid-Lipid Nanoparticle Drug Delivery for Aceclofenac

2012 ◽  
Vol 33 (1) ◽  
pp. 96-102 ◽  
Author(s):  
Narra Kishore ◽  
U. M. Dhanalekshmi ◽  
M. D. Raja ◽  
Saranya Bhavani ◽  
P. Neelakanta Reddy
Keyword(s):  
Drug Delivery ◽  
Solid Lipid Nanoparticle ◽  
In Vitro Evaluation ◽  
Solid Lipid ◽  
Lipid Nanoparticle ◽  
Nanoparticle Drug Delivery

scholarly journals Formulation of Solid Lipid Nanoparticles of Cilnidipine for the Treatment of Hypertension

2019 ◽  
Vol 9 (3) ◽  
pp. 212-221 ◽  
Author(s):  
Aparna Bhalerao ◽  
Pankaj Prakash Chaudhari
Keyword(s):  
Particle Size ◽  
Solid Lipid Nanoparticles ◽  
Encapsulation Efficiency ◽  
Drug Loading ◽  
Lipid Nanoparticles ◽  
Water Soluble ◽  
Solid Lipid Nanoparticle ◽  
Solid Lipid ◽  
Lipid Nanoparticle

Cilinidipine is a fourth generation N and L-type calcium channel antagonists used alone or in combination with another drug to treat hypertension. Cilnidipine is poorly water -soluble, BCS class II drug with 6 to 30 percent oral bioavailability due to first pass metabolism. So to protect the drug from degradation and improve its dissolution, solid lipid nanoparticles were prepared. Glyceryl monostearate was selected as lipid while span 20: tween 20 were selected as surfactant blends. The formulations were evaluated for various parameters, as percent transmittance, drug content, percent encapsulation efficiency; percent drug loading, In vitro drug release and particle size. Optimized formulation was lyophilized using lactose as a cryo-protectant. The lyophilized formulation was evaluated for micromeritic properties, particle size and in vitro dissolution. It was further evaluated for DSC, XRD, and SEM. Percent encapsulation efficiency and percent drug loading of optimized formulation (F3) were 78.66percent and 9.44percent respectively. The particle size of F3 formulation without drug was 204 nm and with the drug was 214 nm. The particle size of the reconstituted SLN was 219 nm. In DSC study, no obvious peaks for cilnidipine were found in the SLN of cilnidipine indicated that the cilnidipine must be present in a molecularly dissolved state in SLN. In X-ray diffractometry absence of peaks representing crystals of cilnidipine in SLN indicated that the drug was in an amorphous or disordered crystalline phase in the lipid matrix. Thus, solid lipid nanoparticle formulation is a promising way to enhance the dissolution rate of cilnidipine. Keywords: Cilnidipine, Solid Lipid Nanoparticle, Hypertension

Sign in / Sign up

Export Citation Format

Share Document